Signos Raises $20M for Glucose Tracking, Expands Dexcom Partnership
Signos, a glucose-tracking startup, has raised $20 million in a funding round backed by Google Ventures, Dexcom, and Blue Cross Blue Shield of Alabama. The company uses continuous glucose monitors (CGMs) to help users manage weight and metabolic health. The new capital will fuel expansion of its partnership with Dexcom, a leading CGM manufacturer, and support product development amid growing demand for weight loss tools. Signos offers a subscription service that pairs Dexcom's CGM sensors with an AI-powered app providing personalized dietary and exercise recommendations. The funding round reflects investor interest in digital health solutions for weight management, a market fueled by the rise of GLP-1 drugs like Ozempic and Wegovy. Signos differentiates itself by focusing on real-time glucose data to optimize eating habits and prevent blood sugar spikes, targeting a broader audience beyond diabetics.
Key facts
- Signos raised $20 million in funding.
- Investors include Google Ventures, Dexcom, and Blue Cross Blue Shield of Alabama.
- The company uses continuous glucose monitors (CGMs) for weight management.
- The funding will expand Signos' partnership with Dexcom.
- Signos offers a subscription service with an AI-powered app.
- Demand for weight loss tools is growing, partly due to GLP-1 drugs.
- Signos targets non-diabetic users for metabolic health optimization.
- The round reflects investor interest in digital health and weight management.
Entities
Institutions
- Signos
- Google Ventures
- Dexcom
- Blue Cross Blue Shield of Alabama
Sources
- Quartz —